RCAG
ABBV icon

Rehmann Capital Advisory Group’s AbbVie ABBV Stock Holding History

Rehmann Capital Advisory Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.76M Sell
12,668
-1,217
-9% -$270K 0.14% 111
2025
Q4 		$3.17M Sell
13,885
-483
-3% -$110K 0.17% 99
2025
Q3 		$3.33M Sell
14,368
-512
-3% -$104K 0.18% 91
2025
Q2 		$2.76M Buy
14,880
+143
+1% +$26.6K 0.17% 97
2025
Q1 		$3.09M Buy
14,737
+319
+2% +$62K 0.19% 91
2024
Q4 		$2.56M Buy
14,418
+551
+4% +$101K 0.16% 104
2024
Q3 		$2.74M Sell
13,867
-380
-3% -$70.9K 0.18% 102
2024
Q2 		$2.45M Buy
14,247
+1,029
+8% +$170K 0.18% 104
2024
Q1 		$2.41M Buy
13,218
+180
+1% +$31K 0.18% 104
2023
Q4 		$2.02M Buy
13,038
+82
+0.6% +$12K 0.17% 106
2023
Q3 		$1.93M Sell
12,956
-95
-0.7% -$13.9K 0.18% 101
2023
Q2 		$1.76M Sell
13,051
-166
-1% -$24.3K 0.16% 107
2023
Q1 		$2.11M Buy
13,217
+520
+4% +$79.5K 0.2% 101
2022
Q4 		$2.05M Sell
12,697
-668
-5% -$102K 0.21% 96
2022
Q3 		$1.79M Sell
13,365
-669
-5% -$96K 0.2% 100
2022
Q2 		$2.15M Buy
14,034
+1,076
+8% +$164K 0.24% 86
2022
Q1 		$2.1M Buy
12,958
+818
+7% +$119K 0.2% 97
2021
Q4 		$1.64M Sell
12,140
-3,170
-21% -$374K 0.15% 121
2021
Q3 		$1.65M Buy
15,310
+2,925
+24% +$334K 0.16% 108
2021
Q2 		$1.4M Buy
12,385
+530
+4% +$59.7K 0.14% 124
2021
Q1 		$1.28M Buy
11,855
+742
+7% +$79.4K 0.13% 132
2020
Q4 		$1.19M Sell
11,113
-1,814
-14% -$174K 0.13% 123
2020
Q3 		$1.13M Buy
12,927
+665
+5% +$62.6K 0.14% 124
2020
Q2 		$1.2M Sell
12,262
-76
-0.6% -$6.69K 0.16% 114
2020
Q1 		$940K Buy
+12,338
New +$1.05M 0.15% 117
2019
Q3 		$811K Sell
10,705
-1,161
-10% -$79.6K 0.1% 107
2019
Q2 		$863K Sell
11,866
-1,467
-11% -$115K 0.11% 156
2019
Q1 		$1.07M Sell
13,333
-491
-4% -$40.2K 0.15% 116
2018
Q4 		$1.27M Sell
13,824
-126
-0.9% -$11.1K 0.19% 62
2018
Q3 		$1.32M Sell
13,950
-901
-6% -$85.4K 0.18% 95
2018
Q2 		$1.38M Buy
14,851
+107
+0.7% +$10.4K 0.2% 90
2018
Q1 		$1.4M Sell
14,744
-424
-3% -$46.6K 0.22% 89
2017
Q4 		$1.47M Sell
15,168
-4,024
-21% -$379K 0.25% 82
2017
Q3 		$1.71M Buy
19,192
+619
+3% +$47.1K 0.31% 65
2017
Q2 		$1.35M Sell
18,573
-2,455
-12% -$165K 0.26% 85
2017
Q1 		$1.37M Sell
21,028
-1,004
-5% -$63.1K 0.23% 89
2016
Q4 		$1.38M Buy
22,032
+2,093
+10% +$128K 0.25% 80
2016
Q3 		$1.26M Sell
19,939
-2,108
-10% -$136K 0.24% 83
2016
Q2 		$1.36M Buy
22,047
+4,358
+25% +$266K 0.26% 83
2016
Q1 		$1.01M Buy
17,689
+2,131
+14% +$119K 0.2% 96
2015
Q4 		$922K Buy
15,558
+2,342
+18% +$135K 0.19% 97
2015
Q3 		$719K Buy
13,216
+2,042
+18% +$133K 0.16% 114
2015
Q2 		$751K Buy
11,174
+1,527
+16% +$99.7K 0.17% 116
2015
Q1 		$565K Buy
9,647
+348
+4% +$21K 0.13% 144
2014
Q4 		$609K Sell
9,299
-9
-0.1% -$567 0.14% 132
2014
Q3 		$538K Buy
9,308
+1,120
+14% +$62.2K 0.13% 141
2014
Q2 		$462K Buy
8,188
+132
+2% +$6.92K 0.11% 157
2014
Q1 		$414K Sell
8,056
-310
-4% -$15.7K 0.11% 157
2013
Q4 		$442K Sell
8,366
-143
-2% -$7.03K 0.13% 148
2013
Q3 		$381K Buy
8,509
+121
+1% +$5.36K 0.12% 157
2013
Q2 		$347K Buy
+8,388
New +$367K 0.12% 156

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Rehmann Capital Advisory Group's ABBV Position: Q1 2026 in Review

Rehmann Capital Advisory Group reduced its AbbVie (ABBV) stake by 8.8% in Q1 2026, selling an estimated $270K and leaving 12,668 shares worth $2.76M. The position accounts for 0.14% of the portfolio, ranked #111.

Rehmann Capital Advisory Group first reported a position in ABBV in Q2 2013 and has held it in 51 quarters since. The position peaked at $3.33M in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Rehmann Capital Advisory Group held 12,668 shares of AbbVie worth $2.76M as of Q1 2026.
  • Rehmann Capital Advisory Group sold 1,217 AbbVie shares in Q1 2026, an estimated $270K.
  • AbbVie made up 0.14% of Rehmann Capital Advisory Group's portfolio in Q1 2026, its #111 holding.
  • Rehmann Capital Advisory Group first reported a position in AbbVie in Q2 2013 and has held it in 51 quarters since.
  • Rehmann Capital Advisory Group's AbbVie position peaked at $3.33M in Q3 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Rehmann Capital Advisory Group's 13F filing for Q1 2026, filed 15 May 2026.